Fully independent intellectual property rights with a number of domestic and foreign authorized patents. Kylonova's Nano Lipid Particle Delivery Platform (NPDP) technology has been proven to be highly targeted, safe and stable by preclinical intravenous administration. The Nano Lipid Particle encapsulates siRNA drugs in nanoparticles composed of multiple lipids. These nano-sized particles can stably flow through bloodstream to the target tissue, and then release the siRNA-content rapidly, uniformly and efficiently into the cells to trigger RNAi.

Features of Nano- Lipid particle delivery platform (NPDP):
● Minimize cytotoxicity and immunotoxicity.

● High encapsulation rate with nearly 100% siRNA encapsulation.

● Good cell affinity and histocompatibility.

● Long-lasting therapeutic effect with low dosage of siRNA drug.

● Low production costs, can be produced in bulk, and sold commercially.